Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Wall St jumps as Gilead data offsets virus fears; financials jump

share with twitter share with LinkedIn share with facebook
07/10/2020 | 04:43pm EDT

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.)

* Gilead analysis shows remdesivir reduced coronavirus death risk

* Carnival rises on plan to resume trips in phases

* Indexes: Dow up 1.4%, S&P 500 up 1.1%, Nasdaq up 0.7% (Updates close with volume, other details)

July 10 (Reuters) - U.S. stocks rose on Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States, and as financial shares surged.

The Nasdaq posted its sixth record closing high in seven days, but the index underperformed both the Dow and S&P 500, in a reversal of the recent trend.

The S&P 500 financials index rose 3.5%, leading sector gains and giving the S&P 500 its biggest boost. Bank of America Corp shares increased 5.5%, Citigroup Inc jumped 6.5% and JPMorgan Chase & Co climbed 5.5% ahead of their financial results next week, which will mark the onset of the second-quarter earnings season.

Rob Haworth, senior investment strategist at U.S. Bank Wealth Management in Seattle, said there was a rotation "from winners into laggards" in Friday's trading, with the earnings period around the corner.

The United States registered the largest single-day increase in new COVID-19 infections globally for the second day in a row on Thursday, forcing Americans to take new precautions. Several states have already backpedaled on reopening plans.

Gilead's remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients, additional data from a late-stage study showed. The drugmaker's shares climbed 2.2% as it said the finding required confirmation in clinical trials.

"That kind of dampened some of the concern that's been building over the past few days around the increased virus cases in the southern states," said Charlie Ripley, senior investment strategist for Allianz Investment Management in Minneapolis.

The Dow Jones Industrial Average rose 369.21 points, or 1.44%, to 26,075.3, the S&P 500 gained 32.99 points, or 1.05%, to 3,185.04 and the Nasdaq Composite added 69.69 points, or 0.66%, to 10,617.44.

For the week, the Dow rose 1%, the S&P 500 gained 1.8% and the Nasdaq jumped 4%.

Overall profits for S&P 500 companies are expected to have fallen more than 40% in the second quarter, which would be the biggest quarterly decline since the financial crisis, according to IBES data from Refinitiv.

The first coronavirus cases in the United States were identified in January and within weeks much of the economy was shut down to slow the spread, throwing millions of Americans into unemployment. Companies across a range of industries have been dealing with the aftermath ever since.

The S&P 500 is up more than 40% from its March bottom, thanks in part to economic data that has pointed to a revival in business activity in June.

Carnival Corp jumped 10.8% after the cruise line operator said it was planning to resume operations in a phased manner and would operate with a smaller fleet on its return.

Netflix Inc rose 8.1% after Goldman Sachs hiked its price target on the video streaming service's shares.

Advancing issues outnumbered declining ones on the NYSE by a 2.87-to-1 ratio; on Nasdaq, a 1.62-to-1 ratio favored advancers.

The S&P 500 posted 19 new 52-week highs and no new lows; the Nasdaq Composite recorded 85 new highs and 17 new lows.

Volume on U.S. exchanges was 9.57 billion shares, compared with the 11.93 billion average for the full session over the last 20 trading days. (Additional reporting by Medha Singh and C Nivedita in Bengaluru; Editing by Marguerita Choy and Maju Samuel)

Stocks mentioned in the article
ChangeLast1st jan.
ALLIANZ SE 0.84% 186.26 Delayed Quote.-14.72%
CARNIVAL CORPORATION & PLC -3.98% 15.19 Delayed Quote.-70.12%
CITIGROUP INC. -0.76% 53.35 Delayed Quote.-33.22%
DJ INDUSTRIAL 1.05% 27976.84 Delayed Quote.-1.97%
GILEAD SCIENCES, INC. 1.09% 68.84 Delayed Quote.5.94%
JPMORGAN CHASE & CO. -0.85% 102.94 Delayed Quote.-26.15%
NASDAQ 100 2.59% 11157.722277 Delayed Quote.24.54%
NASDAQ COMP. 2.13% 11012.238958 Delayed Quote.20.18%
NETFLIX, INC. 1.83% 475.47 Delayed Quote.46.95%
RIPLEY CORP S.A. -0.38% 267 End-of-day quote.-20.82%
S&P 500 1.40% 3380.35 Delayed Quote.3.19%
THE GOLDMAN SACHS GROUP, INC. 0.51% 212.13 Delayed Quote.-8.21%
share with twitter share with LinkedIn share with facebook
Latest news on GILEAD SCIENCES, INC.
12:16aZydus Cadila launches India's cheapest remdesivir version at $37 per vial
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Truvad..
08/11Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
08/11GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
08/11India's shortage of remdesivir is easing, says producer Cipla
08/11GILEAD SCIENCES : Truvada Approved in China for Preventative HIV Use
08/11GILEAD SCIENCES : China National Medical Products Administration Approves Truvad..
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
More news
Financials (USD)
Sales 2020 24 071 M - -
Net income 2020 2 800 M - -
Net Debt 2020 11,6 M - -
P/E ratio 2020 37,4x
Yield 2020 3,93%
Capitalization 86 319 M 86 319 M -
EV / Sales 2020 3,59x
EV / Sales 2021 3,50x
Nbr of Employees 11 800
Free-Float 99,5%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 80,13 $
Last Close Price 68,84 $
Spread / Highest target 40,9%
Spread / Average Target 16,4%
Spread / Lowest Target -9,94%
EPS Revisions
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.65.88%38 435
GENMAB A/S56.53%23 954
BEIGENE, LTD.28.64%18 953